Cancer Chemotherapy and Pharmacology

, Volume 31, Issue 6, pp 442–444

Dose-ranging evaluation of the substituted benzamide dazopride when used as an antiemetic in patients receiving anticancer chemotherapy

  • Stefan C. Grant
  • Mark G. Kris
  • Richard J. Gralla
  • Rebecca A. Clark
  • Leslie B. Tyson
Original Articles Dazopride, Antiemetic, Benzamide

DOI: 10.1007/BF00685032

Cite this article as:
Grant, S.C., Kris, M.G., Gralla, R.J. et al. Cancer Chemother. Pharmacol. (1993) 31: 442. doi:10.1007/BF00685032

Summary

Dazopride, a substituted benzamide structurally related to metoclopramide, is a potent gastric prokinetic agent that prevents cisplatin-induced emesis in animals. Unlike metoclopramide, dazopride has no effect on dopamine receptors and therefore should not produce extrapyramidal side effects. In this dose-ranging trial, 23 patients with cancer receiving chemotherapy known to produce nausea and vomiting received three i.v. infusions of dazopride every 2 h beginning 30 min before the chemotherapy. Seven dose levels were explored ranging from 0.5 to 4.0 mg/kg in each of the three infusions. Toxicities were mild and included sedation, dizziness, visual disturbances, and headaches. All side effects were transient and were not dose-related. Antiemetic effects were observed. Dazopride can be safely given on this schedule at doses of up to 4.0 mg/kg to patients receiving chemotherapy. On the basis of the results of this trial, further studies of this agent are warranted.

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • Stefan C. Grant
    • 2
  • Mark G. Kris
    • 2
  • Richard J. Gralla
    • 2
  • Rebecca A. Clark
    • 2
  • Leslie B. Tyson
    • 2
  1. 1.Ochsner Cancer InstituteNew OrleansUSA
  2. 2.Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of MedicineMemorial Sloan-Kettering Cancer Center and Cornell University Medical CollegeNew YorkUSA

Personalised recommendations